Our hypothesis in this study is the effectiveness of spironolactone as an MR antagonist with anti‐inflammatory and HPA axis regulatory properties on the mood and cognitive symptoms of patients with bipolar disorder in manic episodes. This evidence concerns the gene NR3C2 and bipolar disorder.